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Abstract 
Background: Evidence of health utility changes in patients who suffer from longstanding health complaints attrib-
uted to dental amalgam fillings are limited. The change in health utility outcomes enables calculating quality-adjusted 
life-year (QALY) and facilitates the comparison with other health conditions. The purpose of this study was to estimate 
the validity and responsiveness of the EQ-5D-5L and SF-6D utilities following removal of dental amalgam fillings in 
patients with health complaints attributed to their amalgam fillings, and examine the ability of these instruments to 
detect minimally important changes over time.
Methods: Patients with medically unexplained physical symptoms, which they attributed to dental amalgam 
restorations, were recruited to a prospective cohort study in Norway. Two health state utility instruments, EQ-5D-5L 
and SF-6D, as well as self-reported general health complaints (GHC-index) and visual analogue scale (EQ-VAS) were 
administered to all patients (n = 32) at baseline and at follow-up. The last two were used as criteria measures. Concur-
rent and predictive validities were examined using correlation coefficients. Responsiveness was assessed by the effect 
size (ES), standardized response mean (SRM), and relative efficiency. Minimally important change (MIC) was examined 
by distribution and anchor-based approaches.
Results: Concurrent validity of the EQ-5D-5L was similar to that of SF-6D utility. EQ-5D-5L was more responsive than 
SF-6D: the ES were 0.73 and 0.58 for EQ-5D-5L and SF-6D, respectively; SRM were 0.76 and 0.67, respectively. EQ-
5D-5L was more efficient than SF-6D in detecting changes, but both were less efficient compared to criteria-based 
measures. The estimated MIC of EQ-5D-5L value set was 0.108 and 0.118 based on distribution and anchor-based 
approaches, respectively. The corresponding values for SF-6D were 0.048 and 0.064, respectively.
Conclusions: In patients with health complaints attributed to dental amalgam undergoing amalgam removal, both 
EQ-5D-5L and SF-6D showed reasonable concurrent and predictive validity and acceptable responsiveness. The EQ-
5D-5L utility appears to be more responsive compared to SF-6D.
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Background
Dental amalgam is one of the most widely used den-
tal restorative materials, but safety concerns relating to 
its mercury content have been a topic of discussion for 
many years [1]. This has been a particularly contentious 
issue in Norway, where amalgam use was banned in 
2008, due to environmental considerations. Some peo-
ple with amalgam fillings report health complaints with 
a pattern similar to patients with medically unexplained 
physical symptoms (MUPS), where the symptoms are 
non-specific and a known pathophysiology is missing [2, 
3]. Furthermore, they attribute their health complaints to 
mercury released from their amalgam fillings [3]. Hereaf-
ter we refer to these patients as amalgam patients. Thus, 
assessing health outcomes in amalgam patients and their 
health-related quality of life is essential for clinical prac-
tice and future research strategies. Evidence of health 
utility changes and their validity and responsiveness in 
patients who had longstanding health complaints attrib-
uted to dental amalgam fillings is sparse. Thus, additional 
studies of the change in health utility outcomes that ena-
ble the calculation of quality-adjusted life year (QALY) 
and facilitate the comparison with other health condi-
tions are warranted.
Health state utility (HSU) instruments consist of a 
descriptive system and a predetermined utility weight. 
Utilities are cardinal values that reflect an individual’s 
preferences assigned to each possible combination of 
health states in the descriptive system [4, 5]. They are 
measured on an interval scale with zero reflecting states 
of health equivalent to death and one reflecting full 
health. The EuroQol Five-Dimensional Questionnaire 
(EQ-5D) [6] and the Medical Outcomes Short-Form Six-
Dimension (SF-6D) [7] are the most widely used HSU 
instruments. Such utilities are typically combined with 
survival estimates and aggregated across individuals to 
generate QALYs. QALYs are widely used as a measure of 
health outcomes in economic evaluations of health inter-
ventions. Economic evaluations play an increasing role 
in resource allocation decisions in healthcare, and it is 
important to critically assess the utility weights that form 
the basis for estimating QALY [8].
The EQ-5D has five dimensions, each with three sever-
ity levels in the original version (EQ-5D-3L) and five 
severity levels in the revised version  (EQ-5D-5L). The 
revised version was designed to minimize the ceiling 
effect and improve the sensitivity of the 3L version [9]. 
There are several country-specific EQ-5D-5L valuation 
studies that are currently ongoing (including the elicita-
tion of Norwegian values) or already published [10]. The 
EQ-5D instrument is commonly recommended for eco-
nomic evaluation by reimbursement agencies, such as 
the National Institute for Care and Excellence (NICE) in 
the United Kingdom (UK) [11] and the Norwegian Medi-
cines Agency in Norway [12]. Despite the publication of 
the new English EQ-5D-5L value set, NICE’s interim-
position at the time of the analysis (December 2020) is 
that the validated cross-walk or mapping function by 
van Hout et al. [13] to derive value sets for the EQ-5D-5L 
from the existing 3L version should be used for economic 
evaluation. Based on NICE’s recommendation, the Nor-
wegian Medicines Agency also use the cross-walk value 
sets by van Hout and colleagues for single technology 
assessments [12]. In general, EQ-5D is the most widely 
used HSU instrument in economic evaluation, followed 
by SF-6D [14, 15], and hence the focus of the present 
study.
The psychometric properties of EQ-5D and SF-6D 
have been widely investigated in different patient groups 
as well as in the general population. A recent systematic 
review of the literature demonstrated excellent psycho-
metric properties of the EQ-5D across a broad range of 
populations and conditions [16]. The EQ-5D appears to 
be reliable and valid in the general population [17–22], 
and so does the SF-6D [23–25]. Thus, the reliability and 
validity of such instruments in the general population are 
useful for future population health studies. In addition to 
evidence of validity, both EQ-5D and SF-6D have been 
shown to be responsive in the general population, but the 
mean quality of life measured by EQ-5D is usually higher 
than that of SF-6D [26–28].
Furthermore, both EQ-5D and SF-6D have shown evi-
dence of validity, and responsiveness for a number of dis-
eases [29–36]. One important test of validity is the ability 
of a health outcome measure to reflect relevant changes 
in the health of patients over time, which, specifically, is 
referred to as responsiveness of a measure [37]. Although 
these instruments are becoming more common in clini-
cal practice, the meaning of a change in score on such 
HSU instrument is not straightforward, mainly because 
of the unfamiliar units in the scale of these instruments 
[38]. These health outcome measures can be com-
pleted at baseline and at follow-up, and generate score 
changes, which allows us to easily calculate the statistical 
Trial registration The research was registered at ClinicalTrials.gov., NCT01682278. Registered 10 September 2012, 
https:// clini caltr ials. gov/ ct2/ show/ NCT01 682278.
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significance of the score changes. However, establishing 
the magnitude of the change score in a way easily under-
standable for health professionals, patients and policy-
makers has been difficult, though not impossible [38, 39]. 
Quantifying the magnitude of change that corresponds to 
a minimally important difference would help to address 
this problem [40]. From the patient perspective, Jaeschke 
et al. [41] defined the minimally important difference as 
“the smallest difference in score in the domain of inter-
est which patients perceive as beneficial”. Although we 
have some knowledge about validity and responsive-
ness of EQ-5D and SF-6D in some diseases [31, 35, 38, 
42–44], we know very little about their responsiveness 
and validity in patients with MUPS who attribute their 
health problems to dental amalgam. To our knowledge, 
the minimally important difference of EQ-5D and SF-6D 
for amalgam patients has not been reported so far.
Therefore, we aimed to examine the health utility 
changes associated with dental amalgam fillings removal 
in a group of amalgam patients in terms of the two most 
widely used HSU instruments; the EQ-5D-5L and SF-
6D. More specifically, this analysis had two objectives: 
(i) examine the concurrent and predictive validity as well 
as responsiveness to change of the EQ-5D-5L and SF-6D 
utilities in a prospective cohort study; and (ii) assess the 
ability of the EQ-5D-5L and SF-6D instruments to detect 
minimally important changes over time.
Methods
Data and study design
The analyses are based on data from a prospective cohort 
in Norway [45]. The study comprised three groups 
recruited separately: (i) patients with MUPS, which they 
attributed to dental amalgam restorations who wished to 
have their amalgam fillings removed (Amalgam cohort); 
(ii) patients with MUPS recruited from general practice 
without symptom attribution to amalgam fillings (MUPS 
cohort); and (iii) participants who identified themselves 
as healthy (Healthy cohort).
This analysis is restricted to the Amalgam cohort, 
which was the main target group. The presence of at least 
one amalgam fillings is the primary criteria for inclu-
sion in amalgam cohort. Other inclusion criteria were 
unspecific health complaints attributed to dental amal-
gam restorations at least for three months, wish to have 
all amalgam fillings removed, ability to comply with the 
protocol, age between 20 and 70 years, permanent resi-
dence in Norway. Detailed eligibility criteria and recruit-
ment procedures are reported elsewhere [45]. In general, 
a total of 49 participants were initially assessed for inclu-
sion in the Amalgam cohort. Of these, 12 subjects did not 
fulfill the eligibility criteria and 5 did not complete the 
amalgam removal, and were excluded from the analysis. 
A total of 32 participants were available for the follow-up 
analysis.
Variables
At baseline, the socio-economic variables age, gender, 
marital status, education, household income and employ-
ment status were documented. Patients also completed 
the EQ-5D-5L and the short-form 36 questionnaires 
(SF-36) at baseline and at follow-up (12  months after 
amalgam removal). Based on SF-36 questionnaire, we 
calculated the SF-6D utility [7]. Patients also rated their 
overall health on the visual analogue scale (EQ-VAS) and 
documented general symptoms in a health complaints 
index (GHC-index) questionnaire. The latter two (GHC 
and EQ-VAS) were used as the criteria variable against 
which the utility instruments were compared.
Europol Five‑Dimensional Questionnaire (EQ‑5D‑5L)
At the time of this analysis, the psychometric property of 
the EQ-5D-5L was not yet studied in Norwegian popu-
lation. However, a study of the Norwegian population 
norms for EQ-5D-3L [46] demonstrated that it can be 
used as reference data to compare patients with specific 
conditions and to assess the burden of the condition in 
question. The EQ-5D-5L1 describes health along five 
dimensions: mobility, self-care, usual activities, pain/
discomfort and anxiety/depression. Each dimension 
is assessed by a single question on a five-point ordinal 
scale (no problems, slight problems, moderate problems, 
severe problems, extreme problems/unable to). Thus, the 
EQ-5D-5L defines  55 = 3125 possible health states. These 
health states can be converted to a single EQ-5D-5L 
summary index by applying scores from a standard set 
of values (utility weights) derived from general popula-
tion samples [47]. In the absence of Norwegian utility 
weights, we used utility weights that were derived from 
members of the English general public using composite 
time-trade-off [48]. We also tested the consistency of 
our results by applying the United Kingdom (UK) utility 
weights calculated using cross-walk algorithm (mapping 
the EQ-5D-5L descriptive system data onto the 3L value 
set) from van Hout et al. [13]. The UK cross-walk value 
set is denoted as EQ-5D-CW to distinguish it from the 
directly elicited English value set, defined as EQ-5D-5L. 
The minimum value for the worst health state (“the pits”) 
was − 0.285 for the English EQ-5D-5L value set and 
-0.594 for the UK EQ-5D-CW.
The full health state, which is the absence of any 
problem on each of the 5-dimensions of the EQ-5D-5L 
1 EQ-5D-5L was available after registration at EuroQol Group http:// www. 
euroq ol. org.
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(11111), gives a utility of 1. In contrast, the worst health 
state—which corresponds to level-5 on each dimen-
sion (55555); i.e., unable to walk about, unable to wash 
or dress myself, unable to do my usual activities, have 
extreme pain/discomfort, and extremely anxious/
depressed—produces a negative utility. The exact value of 
health state utilities vary depending on which country’s 
value set (utility weight) has been applied [8]. In general, 
negative utilities imply that patients would prefer to die 
than live with such poor health states. Thus, utility is the 
preference for a health state (rated in the presence of 
choice) relative to full health (scored 1) and death (scored 
0), and values below zero representing health states 
worse than being dead.
The Short‑Form Six‑Dimension (SF‑6D)
The SF-6D2 is derived from 11 items of the SF-36 or 
SF-12 health survey, and has six-dimensions: physical 
functioning, role functioning, social functioning, bod-
ily pain, mental health, and vitality [7, 49]. Each dimen-
sion has four to six severity levels, defining 18 000 unique 
health states. Studies for the population norms of the 
SF-36 in the Norwegian general population supported 
the validity of the instrument [50, 51]. Since there is no 
Norwegian-specific SF-6D value sets, the utility weights 
for SF-6D health states are based on members of the 
UK general population, and were elicited using standard 
gamble [7]. The maximum SF-6D utility is 1, the mini-
mum score for a living person (the worst state) is 0.296, 
and the state being dead is scored as zero.
EuroQol visual analogue scale (EQ‑VAS)
For the EQ-VAS, which is part of the EQ-5D-5L ques-
tionnaire, patients are asked to indicate their overall 
health on a vertical visual analogue scale, ranging from 0 
(worst imaginable health) to 100 (best imaginable health). 
EQ-VAS can be used to measure a multitude of subjec-
tive conditions and would seem particularly appropriate 
for conditions related to MUPS.
General health complaints (GHC‑index)
The GHC-index is the sum score of 12 items, each scored 
by use of numeric rating scales ranging from 0 to 10 [52]. 
The items are: Musculoskeletal complaints, gastrointes-
tinal complaints, cardiovascular complaints, skin prob-
lems, complaints related to eyes/sight, complaints related 
to ears/hearing/nose/throat, tiredness, dizziness, head-
aches, memory problems, difficulty concentrating, and 
anxiety/depression. We reversed the score values (GHCr) 
to obtain a scale in which higher scores represent better 
health (i.e., less health complaints) and positive change 
scores represented improvement. The GHC-index is not 
utility-weighted, and the index value is the crude sum of 




Concurrent validity of each of the two HSU instruments 
was tested by computing Spearman’s rank correlation 
coefficients (rho, ρ) between the utility instruments and 
each of the criterion measures at the baseline. A non-par-
ametric Spearman’s rank correlation coefficient was cho-
sen based on the measures’ score distributions. Because 
health is not a static variable, we repeated the concurrent 
validity analyses in the follow-up period.
Predictive validity refers to the association between 
one variable and an outcome assessed at a later time [53, 
54]. In this study, predictive validity was calculated as the 
correlation (ρ) between the HSU instruments at baseline 
and the criterion measures at follow-up. The strength 
of the relationship was considered low/weak (ρ < 0.25), 
fair (ρ = 0.25–0.50), good (ρ = 0.50–0.75), and excellent 
(ρ > 0.75) [16].
Responsiveness
Responsiveness is a measure of the sensitivity of an 
instrument to change in health status over time. First, 
changes in all health outcome measures at the baseline 
and follow-up were compared using paired t-tests. Sec-
ond, responsiveness was assessed using effect size (ES), 
standardized response mean (SRM) and relative effi-
ciency (RE). ES was defined as the mean observed change 
from baseline to follow-up divided by the standard devia-
tion of the baseline score [55]. SRM was calculated in the 
same way as the ES, but using the standard deviation of 
the pre-post differences as denominator. ES and SRM 
were classified as large (≥ 0.8), moderate (0.5–0.79) or 
small (< 0.5) [56, 57]. Both ES and SRM are standardized 
measures of change over time in health, independent of 
sample size [58]. RE was calculated by taking a ratio of 
F-statistics (or squared t-statistics), where the criterion 
measure served as the reference. An RE value less than 
1 implies that the standard criterion measure is more 
responsive than the utility instruments, and the converse 
is true for an RE value of greater than 1. A coefficient of 1 
indicates similarity in the efficiency of the two measures.
Minimally important change
Minimally important change (MIC) is defined as the 
smallest change in score which is perceived as impor-
tant by patients or clinicians [59]. In this study, MIC 
2 SF-6D was available after registering at University of Sheffield https:// licen 
sing. sheffi eld. ac. uk/ produ ct/ SF- 6D.
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was assessed using both distribution and anchor-based 
approaches. Distribution-based methods mainly measure 
minimally detectable change (the smallest change that 
can be detected by the instrument beyond measurement 
error) [60]. Nonetheless, the term MIC is used for both 
approaches in this paper. For distribution-based calcula-
tions, MIC was defined as half baseline standard devia-
tion (0.5*SD) for the effectiveness of the intervention [61]. 
For the anchor-based method, MIC is usually estimated 
by comparing change scores with an external anchor. 
One of the commonly used anchors for establishing MIC 
is global ratings of change. For the present analysis, we 
used patients’ self-reported global ratings of results of 
amalgam fillings removal as external anchor. Participants 
were asked “How do you rate the results of the amalgam 






The relationship between the global ratings of change 
question and changes in EQ-5D-5L and SF-6D utilities 
was assessed by calculating the change in EQ-5D-5L 
and SF-6D utilities from baseline to follow-up for each 
patient, and likewise for the GHCr-index and EQ-VAS. In 
accordance with previous studies, we considered patients 
whose global ratings of change score was 3 or 5 as hav-
ing experienced some change equivalent to the MIC [38, 
62]. For participants who reported a worsening of health 
(rating scale of 5), the sign of the change in each health 
outcome measure was reversed. The MIC was then taken 
as the mean changes in scores of the patients who scored 
3 or 5.
Finally, we applied predictive modelling, which is a 
newly proposed anchor-based method for MIC [63]. 
Here, Item-2 of the SF-36 was used as the anchor, which 
is described as: “Compared to one year ago, how would 
you rate your health in general now?”.
1. Much better now than 1 year ago.
2. Somewhat better now than 1 year ago.
3. About the same.
4. Somewhat worse now than 1 year ago.
5. Much worse now than 1 year ago.
This score was transformed into a change score by 
taking the difference between baseline and follow-up to 
produce an anchor. Then, we used exact logistic regres-
sion to predict whether a patient belongs to the improved 
(≥ 1) or not improved group (≤ 0) on this anchor using 
the change in each of the health outcome measure as 
the predictor. When sample sizes are small or the data 
are skewed, exact conditional inference is often more 
appropriate compared to the conventional method of 
logistic regression [64]. The MIC was estimated from the 
equation: MIC = [ln(OddsPre)− C]/β , where C is the 
intercept, β is the regression coefficient, and  OddsPre is 
pre-odds of being improved and given by P/(1 − P), with 
P the proportion improved based on the anchor [63].
To confirm the usefulness of the anchors, Spearman’s 
rank correlations were computed between the health 
outcome score changes and the two anchors. A correla-
tion coefficient of 0.30 or more is considered sufficiently 
strong to allow for computation of MIC [65].
Results
Baseline characteristics
Demographic and socio-economic characteristics are 
presented in Table 1. Most patients were female (59.4%), 
with the majority living with a partner or spouse (81.3%). 
Mean age of patients at baseline was 52 (SD = 7.5) years. 
Boxplots illustrate that the distributions were wide for all 
five health outcomes measures used, both at baseline and 
at follow-up (Fig. 1). No patient reported either the worst 
or best possible health on any of the health outcome 
measures. 
Concurrent and predictive validity
Spearman’s correlation coefficients for the HSU instru-
ments and the criteria measures (GHCr-index and EQ-
VAS) at baseline and follow-up periods are presented in 
Table 2. For the EQ-5D-5L, the correlations with GHCr-
index were relatively lower at baseline (ρ = 0.48) than at 
follow-up (ρ = 0.52), with a reverse pattern for EQ-VAS 
Table 1 Baseline sample characteristics for patients with MUPS 
undergoing amalgam removal
MUPS medically unexplained physical symptoms
Characteristics N (%)
Female gender 19 (59.4)
Education
 Lower & upper secondary 14 (43.8)
 College, < 4 years 11 (34.4)
 College, 4 + years 7 (21.9)
Living with partner
 No 6 (18.7)
 Yes 26 (81.3)
Income
 Low 9 (25.8)
 Middle income 13 (41.9)
 High income 10 (32.3)
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Fig. 1 Box plots showing distributions of health outcomes at the baseline and follow-up for amalgam patients. A box indicates the positions of 
the upper and lower quartiles; the interior of the box indicates the interquartile range; the crossbar (middle line) that intersects the box shows the 
median of the dataset; a whisker (line) that extends to the extreme of the distribution from lower hinge and upper hinge indicates the minimum 
and maximum values, respectively. EQ-5D-5L EuroQol 5-dimensional 5-level questionnaire; EQ-5D-CW EQ-5D cross-walk value set; SF-6D Short-form 
6-dimension; GHCr (reversed) general health complaints; EQ-VAS (EuroQol) visual analogue scale; HSU Health state utility
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(higher at baseline). The results were quite similar for the 
EQ-5D-CW and the SF-6D. These correlations were gen-
erally high, indicating good concurrent validities of the 
HSU instruments. With regard to predictive validity, the 
EQ-5D-5L and SF-6D at the baseline period predicted 
both the GHCr-index and EQ-VAS at follow-up period 
fairly well, with SF-6D performing slightly better. The 
EQ-5D-CW fairly predict EQ-VAS, but slightly week in 
predicting GHCr-index.
Responsiveness and minimally detectable change
Responsiveness results are presented in Table 3. The base-
line means (SD) EQ-5D-5L and SF-6D utilities were 0.61 
(0.22) and 0.60 (0.10), respectively. Mean EQ-5D-CW 
was 0.10 lower than mean EQ-5D-5L both in the base-
line and follow-up. All health outcome measures showed 
significant improvement at follow-up (p < 0.01, paired 
t-tests). The mean change (SD) for EQ-5D-5L was 0.158 
(0.207) and that of SF-6D was 0.056 (0.084). The mean 
change for the EQ-5D-CW is quite like the EQ-5D-5L. 
The corresponding values for GHCr-index and EQ-VAS 
were 12.78 (15.87) and 12.53 (15.23), respectively.
Generally, all health outcome measures exhibited mod-
erate responsiveness as measured by ES and SRM. Except 
the SF-6D, all health outcome measures revealed similar 
ES (≈ 0.70). The SF-6D utility instrument had relatively 
lower responsiveness (ES = 0.58) (Table  3). In terms of 
SRM, both criteria variables revealed large responsive-
ness (SRM > 0.80), while the two utility instruments indi-
cated moderate responsiveness, as expected. All HSU 
instruments had RE below 1, indicating less efficiency 
in detecting changes in health over time as compared 
to GHCr-index  (though statistically insignificant, except 
SF-6D). Both EQ-5D-5L and EQ-5D-CW were more effi-
cient when compared with SF-6D.
MIC estimations derived from the anchor- and 
distribution-based methods, as well as the correla-
tions between health outcome score changes and the 
two anchors are presented in Table  4. All health out-
come score changes were significantly correlated with 
responses to both anchors; accordingly, the two global 
ratings of change were considered appropriate anchors 
for measuring all score changes.
For the anchor-based method, the MIC estimation was 
0.118 for the EQ-5D-5L, 0.124 for EQ-5D-CW and 0.064 
for SF-6D. The corresponding MIC was 9.158 for the 
GHCr-index and 8.789 for the EQ-VAS score. The dis-
tribution-based estimation (i.e., half SD of baseline) gave 
0.108 for the EQ-5D-5L, 0.115 for EQ-5D-CW and 0.048 
for the SF-6D. Both the distribution- and anchor-based 
estimations produced fairly similar results. The predic-
tive modelling approach also produced similar findings, 
confirming the consistency of our results.
Discussion
In this analysis of patients with health complaints attrib-
uted to their amalgam fillings, validity and responsiveness 
to change from baseline to follow-up (12  months after 
removal of amalgam fillings) was assessed. This study is 
Table 2 Correlations as measures of concurrent and predictive 
validities for EQ-5D-5L and SF-6D utilities
a Correlations between utility instruments at baseline and criteria variables 
at follow-up, which are classified as weak (ρ < 0.25), fair (0.25 to 0.50), good 
(0.50 to 0.75), and excellent (> 0.75). EQ-5D-5L EuroQol 5-dimensional 5-level 
questionnaire; EQ-5D-CW EQ-5D cross-walk value set; SF-6D Short-form 





 GHCr-index 0.48 0.46 0.42
 EQ-VAS 0.74 0.68 0.70
Follow-up
 GHCr-index 0.52 0.56 0.50
 EQ-VAS 0.55 0.58 0.64
Predictive validitya
GHCr-index 0.25 0.22 0.31
EQ-VAS 0.31 0.28 0.46
Table 3 Measures of responsiveness for health outcome measures
a  GHCr-index has been used as a reference in the calculation of RE. ΔMean Mean change between baseline and follow-up; SD standard deviation; SE bootstrapped 
standard error (with 1000 iterations); ES effect size; SRM standardized response mean; RE relative efficiency; EQ-5D-5L EuroQol 5-dimensional 5-level questionnaire; 
EQ-5D-CW EQ-5D cross-walk; SF-6D Short-form 6-dimension; GHCr (reversed) general health complaints; EQ-VAS (EuroQol) visual analogue scale
Mean (SD) Paired t-test Responsiveness
Baseline Follow-up ∆Mean (SD) p value ES (SE) SRM (SE) RE (SE)
EQ-5D-5L 0.61(0.22) 0.77 (0.16) 0.158 (0.207) < 0.001 0.73 (0.17) 0.76 (0.18) 0.90 (0.58)
EQ-5D-CW 0.51(0.23) 0.67 (0.17) 0.162 (0.220) 0.002 0.70 (0.16) 0.75 (0.19) 0.84 (0.57)
SF-6D 0.60 (0.10) 0.65 (0.12) 0.056 (0.084) 0.001 0.58 (0.19) 0.67 (0.23) 0.68 (0.34)
GHCr-indexa 76.72 (17.75) 89.49 (14.36) 12.78 (15.87) < 0.001 0.72 (0.19) 0.81 (0.18) 1 (Ref.)
EQ-VAS 49.90 (18.21) 62.44 (16.72) 12.53 (15.23) < 0.001 0.69 (0.17) 0.82 (0.19) 1.05 (0.48)
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the first to assess the validity and responsiveness of two 
commonly used utility instruments—the EQ-5D-5L 
and SF-6D—in patients with MUPS who attribute their 
health problems to amalgam fillings. Our results have 
shown key differences in the ability of the EQ-5D-5L and 
SF-6D to measure longitudinal changes. Although both 
EQ-5D-5L and SF-6D demonstrated significant change in 
health over time, the EQ-5D-5L was more responsive to 
change than the SF-6D. This finding is in line with previ-
ous studies of the two utilities in other health conditions 
[31, 38, 66].
The correlation between the utility and criterion meas-
ures showed fair concurrent validity at both baseline and 
follow-up. The high correlations between criteria meas-
ures and the two HSU instruments generally demon-
strated acceptable concurrent validity of EQ-5D-5L and 
SF-6D. At the end of the follow-up period, correlations 
were increased between the SF-6D and criterion meas-
ures unlike EQ-5D-5L. The main explanation could be 
that SF-6D captures most of the description of the more 
specific and comprehensive scale of GHCr-index and 
EQ-VAS compared to the EQ-5D-5L. For instance, both 
SF-6D and GHCr-index focus on physical functioning 
and energy, which the EQ-5D-5L lacks. This implies that 
the intervention was followed by reduction of intensity of 
the health complaints, increasing its consistency with the 
more specific and comprehensive scales of criteria meas-
ures [31].
Further, our findings showed that EQ-5D-5L and SF-6D 
had sufficient predictive validity—the utility instruments 
at the baseline would fairly predict the GHCr-index at 
follow-up, indicating that they accounted for a significant 
amount of variance in predicting amalgam treatment out-
comes at follow-up. The predictive power may depend on 
the severity of the condition, which could not be inves-
tigated due to small sample size. However, regression to 
the mean could partly be considered as a possible cause 
of an observed change, because regression to the mean in 
repeated data is a ubiquitous phenomenon [67, 68].
With regard to responsiveness, our results gener-
ally showed moderate to large responsiveness for all the 
health outcome measures. The EQ-5D-5L and SF-6D 
were moderately responsive to changes based on both 
the ES and SRM statistics, whereas the EQ-VAS and 
GHCr-index were highly responsive to changes on the 
SRM and relative efficiency statistics. Other studies in 
different diseases found similar results [31, 66]. The high 
responsiveness and greater efficiency would suggest that 
GHCr-index and EQ-VAS are suitable criteria measures 
for amalgam patients. However, a firm conclusion that 
the GHCr-index and EQ-VAS are more responsive than 
the HSU instruments as a measure of health in amalgam 
patients would be premature, because the findings are 
based on an analysis with a small sample size.
To our knowledge, empirical work has not been per-
formed to assess the responsiveness and MIC of the EQ-
5D-5L and the SF-6D in patients with MUPS attributed 
to amalgam fillings. Both the anchor-based and distribu-
tion-based approaches have shown similar MIC values. 
While the MIC values calculated by the distribution- 
and anchor-based methods were fairly similar for the 
EQ-VAS and the GHCr-index, a substantial difference 
was observed between the EQ-5D-5L and SF-6D. The 
MIC difference between the two utility instruments was 
mainly attributable to their scale difference. For instance, 
the effective scale length for the English EQ-5D-5L is 
1.285 (i.e., from -0.285 to 1), whereas the effective scale 
length for the SF-6D is 0.704 (i.e., 0.296 to 1). The scale 
adjusted anchor-based MIC for EQ-5D-5L was 0.092 
(= 0.118/1.285), which is equivalent to that of SF-6D 
(0.091 = 0.064/0.704). Similar results were observed for 
the distribution-based MIC. Thus, the scale difference 
mainly accounts for the difference in their MIC values. 
Our finding is consistent with previous studies for EQ-
5D-3L and SF-6D [38]. This implies that it is not only the 
description of health but also the range of the instrument 
scale that is crucial in the assessment of MIC for the HSU 
instruments. While EQ-5D-5L applied time-trade-off for 
Table 4 Minimally important changes for those who reported some change
a  Correlations of GRC variables with score changes of utility and criteria variables (a value of ρ 0.30 and above is sufficiently large to use the anchors for the 
calculation of MIC). GRC Global rating of change (1 = evaluation of amalgam removal results, & 2 = item-2 of the SF-36); CI (bootstrapped) confidence interval (with 
1000 iterations); SD (baseline) standard deviation; MIC minimally important change; EQ-5D-5L EuroQol 5-dimensional 5-level questionnaire; SF-6D Short-form 
6-dimension; GHCr (reversed) general health complaints; EQ-VAS (EuroQol) visual analogue scale
Correlations (ρ)a 0.5 SD Anchor-based method Predictive modelling
GRC1 GRC2 MIC MIC 95% CI MIC 95% CI
EQ-5D-5L 0.53 0.49 0.108 0.118 0.038–0.198 0.103 0.062–0.237
EQ-5D-CW 0.52 0.45 0.115 0.124 0.036–0.213 0.101 0.018–0.325
SF-6D 0.45 0.51 0.048 0.064 0.029–0.099 0.056 0.020–0.143
GHCr-index 0.36 0.31 8.876 9.158 1.798–16.517 8.786 3.096–17.804
EQ-VAS 0.45 0.36 9.106 8.789 2.580–14.999 9.076 3.525–18.624
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elicitation of utility weights, SF-6D used standard gam-
ble. Thus, their difference arises primarily because of 
scale effect brought up by the methodological approach 
used to construct preference weights [69].
The EQ-5D-5L and SF-6D are designed to be utilized to 
calculate QALYs (measured in units of time) for the esti-
mation of cost-effectiveness. Therefore, the validity of the 
instruments will translate into the validity for the cost-
effectiveness estimates. Usually, the EQ-5D-5L tends to 
produce larger change scores than the SF-6D and hence 
produces more favorable cost-effectiveness ratios than 
the SF-6D, especially when baseline health was strongly 
compromised as the case in the present study [70]. Simi-
larly, other studies found higher QALY gains using the 
EQ-5D-3L than the SF-6D [33, 36, 71, 72].
Both HSU instruments had good concurrent valid-
ity and fair predictive validity in patients with amal-
gam removal. While EQ-5D consistently showed better 
responsiveness, SF-6D had slightly better predictive 
power. The results also depend on the choice of the cri-
teria variables and the disease conditions in question. 
Being more responsive, the EQ-5D could be more appro-
priate for measuring the burden of health conditions 
or for generating QALYs that can be used in economic 
evaluation studies than the SF-6D in line with previous 
study [73]. Nevertheless, both HSU instruments are valid 
economic evaluation instruments but not interchange-
able and hence, the choice of HSU instrument for meas-
uring utility can lead to different results in the context of 
cost per QALY estimates. This suggests that researchers 
and policy makers using cost-effectiveness analysis must 
consider several sources of evidence to select an instru-
ment for measuring utility. Since there is no gold stand-
ard, decision makers need to consider an instrument that 
enable them to make consistent decisions across a broad 
range of populations and conditions. Further research is 
required, particularly across the full severity range of the 
utility scale, to identify the practical performance of util-
ity instruments and their implications for cost-per-QALY 
estimates and health care decision making.
The main strength of this study is that it applied several 
techniques to validate instruments to elicit health out-
come measures, including ES, SRM and relative efficiency 
as well as mean change scores to measure the responsive-
ness, which enables us to confirm the consistency of our 
results. Further, we applied distribution-based and mul-
tiple anchor-based assessment of MIC for the EQ-5D-5L 
and SF-6D that substantiate the stability of our findings. 
Although there is no single gold standard external crite-
rion, anchor-based techniques rely most commonly on 
the use of a subjective global assessment of change [74], 
which have the advantage of linking the change in a given 
score to the patient’s perspective [58].
This study has also a number of limitations. Because 
global assessment is based on the recall ability of 
patients about their earlier health status, the use of the 
retrospective global assessment as an external crite-
rion of score changes can be problematic. That is, there 
could be a potential for response shift and recall bias 
due to the prolonged time between the baseline and 
follow-up periods [38]. Thus, the MIC may change over 
time and recall bias and response shift may pose a prob-
lem, which needs to be investigated further. Further-
more, only a few patients reported deterioration and, 
hence, we did not analyse MIC for the clinically dete-
riorated patients separately. The small sample size also 
precluded the use of subgroup analyses. Thus, although 
this study has used several methods to quantify MIC, it 
is important to further test and validate estimates using 
other methods and larger sample sizes.
Conclusions
In conclusion, the concurrent and predictive valid-
ity from all health outcomes were acceptable. The dis-
crepancy in responsiveness of EQ-5D-5L and SF-6D in 
detecting change was mainly attributed to their scale 
differences. Thus, both EQ-5D-5L and the SF-6D can 
be used in clinical trials including this group of patients 
where a known effective intervention is to be applied. 
The MIC estimate for the EQ-5D-5L and SF-6D will be 
useful in interpreting EQ-5D-5L and SF-6D utilities, 
both in individuals and in groups of patients partici-
pating in trials as well as in the planning of new trials. 
The differences in the magnitude of the absolute change 
scores have important implications for cost-effective-
ness analyses. Economic evaluation studies should 
be based on health utilities elicited with instruments 
that have validated measurement properties for the 
intended population.
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